Dr. Can Cui is a partner in Goodwin’s Life Sciences group. His practice focuses on technology transactions and investment in the life sciences industry, especially those transactions related to China, including cross-border technology licensing and acquisition, collaboration and strategic partnership, joint venture (JV), and other forms of investment.

Dr. Cui has extensive experience representing both licensors and licensees in U.S.-China life sciences licensing transactions. In private equity and venture capital transactions, he regularly represents institutional and individual investors, established life sciences companies and startups in intellectual property (IP) due diligence and the negotiation and drafting of related investment documentation. He also advises clients on IP aspects of mergers and acquisitions.

Dr. Cui has deep knowledge of China’s increasingly complex regulatory landscape, including not only the IP laws, but also regulations governing cross-border transactions, such as technology import and export regulations and regulations of human genetic resources. He also has rich experiences in corporate matters, patent prosecution and IP dispute resolution, which, together with his scientific background, make him a go-to person for advice in various legal matters life sciences companies may have.

In addition to his legal services to the life sciences industry, Dr. Cui is also an active participant in a wide variety of pro bono matters. He has been a recipient of the California Lawyers Association’s Wiley W. Manuel Certificate for Pro Bono Legal Services in recent years.

崔粲博士是高赢国际律师事务所生命科学业务部合伙人,其业务专注于生命科学行业的技术交易和投资项目,尤其是与中国相关的交易,包括跨境技术许可和收购、合作和战略伙伴协议,以及合资和其他形式的投资项目。

崔博士在中美生命科学许可交易中代理许可方和被许可方都有丰富的经验。在私募股权和风险投资交易中,他经常为机构和个人投资者、著名的生命科学公司和初创公司提供法律服务,包括知识产权尽职调查和投资文件的谈判与撰写。此外,他还在并购交易中向客户提供知识产权方面的专业咨询。

崔博士对于中国日益复杂的监管环境有著深厚的知识,不仅涵盖了知识产权法领域,还包括管理跨境交易的法规,如技术进出口法规,以及人类遗传资源方面的法规。此外,他在公司事务、专利申请和知识产权争议解决等方面也具有丰富的经验,这些经验,加上他的科学背景,使他为生命科学公司面临各种法律问题时的首选顾问。

除了为生命科学行业提供法律服务外,崔博士还积极参与各种公益法律事务。崔博士近年来屡次获得加州律师协会颁发的Wiley W. Manuel公益法律服务证书
Areas of Practice
TÄTIGKEITSFELDER
Domaines D’Expertise
业务范围

Experience

ERFAHRUNG

EXPÉRIENCE

工作经历

Dr. Cui has advised the following companies, among others, in the life sciences industry in the following transactions and matters, among others:

  • ACROBiosystems Inc.: various licensing, collaboration, sales, distribution, consulting and investment transactions, and IP matters;*

  • A publicly traded, global, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies: various collaboration, licensing, and services transactions, and employee IP matters;*

  • A biotechnology company that leverages revolutionary drug targets to develop and commercialize transformational therapies in autoimmune diseases, cancers and transplantations: various services, manufacturing, and consulting agreements;*

  • A Shanghai-based biopharma company developing next generation anti-cancer therapies: various licensing and co-development transactions, and IP due diligence matters;*

  • A clinical stage biopharmaceutical company with the goal of curing cancer by developing novel T-cell therapies that harness the evolutionary power of the immune system: various licensing, collaboration, and clinical services transactions, and China IP, JV and regulatory matters;*

  • Evive Biotechnology (Shanghai) Ltd.: various licensing and collaboration transactions, including with the Memorial Sloan-Kettering Cancer Center, and patent applications;

  • GenScript Biotech Corporation and its clinical-stage oncology biotech subsidiary, Legend Biotech Corporation:

    • licensing transactions, including with Amgen and Noile-Immune Biotech, Inc., respectively;*

    • technology services transactions;*

    • strategic collaborations, including with REMD Biotherapeutics Inc.;*

    • various strategic partnership transactions;*

    • acquisition of CustomArray, Inc.;* and

    • Chinese IP law and compliance matters;*

  • HebeCell Corp: various licensing and collaboration transactions;*

  • Helio Health Inc.: various licensing transactions, including with universities, and patent applications;*

  • Livzon Pharmaceutical Group Inc.:

    • $33 million Series B financing of Elicio Therapeutics;*

    • $47 million Series B financing of Carisma Therapeutics;* and

    • U.S. regulatory advice;*

  • Qilu Pharmaceutical Co., Ltd.: various collaboration and licensing transactions;

  • T-Cure Bioscience, Inc.:

    • license agreement with Immunotech Biopharm Ltd;* and

    • clinical research agreement with Rutgers, The State University of New Jersey;*

  • A global leader of 3D printing pharmaceuticals: various collaboration and services transactions, and employee and consultant IP matters;

  • Vazyme Biotech Co., Ltd: IP dispute and product distribution matters;* and

  • Warburg Pincus Asia LLC:

    • freedom-to-operate and other China IP due diligence matters;*

    • 1.2 billion Series B financing of Haihe Pharmaceutical;* and

    • $123 million Series D financing of Abbisko Therapeutics.*
 
*Denotes experience prior to joining Goodwin.

崔博士曾在以下和其他的交易和事项中向生命科学行业的以下和其他公司提供法律咨询:

  • ACROBiosystems公司:各种许可、合作、销售、分销、咨询和投资交易,以及知识产权事宜*

  • 一家致力于转化基于抗体的新型癌症免疫疗法的发现和开发的上市全球性临床阶段生物制药公司:各种合作、许可和服务交易,以及员工知识产权事宜*

  • 一家利用革命性的药物靶点开发和商业化自身免疫疾病、癌症和移植的转化疗法的生物技术公司:各种服务、制造和咨询协议*

  • 一家开发下一代抗癌疗法的上海生物制药公司:各种许可和合作开发交易,以及知识产权尽职调查事项*

  • 一家以通过开发利用免疫系统进化能力的新型T细胞疗法来治疗癌症为目标的临床阶段生物制药公司:各种许可、合作和临床服务交易,以及中国知识产权、合资企业和监管事项*

  • 亿一生物医药开发(上海)有限公司:各种许可和合作交易,包括与Memorial Sloan-Kettering Cancer Center的合作,以及专利申请

  • 金斯瑞生物科技股份有限公司及其临床阶段肿瘤生物技术的子公司南京传奇生物科技有限公司:

    • 别与安进和Noile-Immune Biotech公司的许可交易*

    • 术服务交易*

    • 战略合作事宜,包括与REMD Biotherapeutics公司的合作*

    • 各种战略伙伴交易*

    • CustomArray公司*以及

    • 中国知识产权法和合规事项*

  • HebeCell公司:各种许可和合作交易*

  • Helio Health公司:包括与大学之间的各种许可交易和专利申请*

  • 丽珠医药集团股份有限公司:

    • Elicio Therapeutics3300万美元B轮融资*

    • Carisma Therapeutics4700万美元B轮融资*以及

    • 美国监管咨询*

  • 齐鲁制药集团:各种合作及许可交易

  • T-Cure Bioscience公司:

    • Immunotech Biopharm公司的许可协议*以及

    • 与罗格斯,新泽西州立大学的临床研究协议*

  • 一家3D打印药物的全球领导者:各种合作和服务交易,以及员工和顾问知识产权事宜
  • 南京诺唯赞生物科技股份有限公司:知识产权纠纷和产品分销事宜*

  • 华平投资:

    • 自由使用权和其他中国知识产权尽职调查事项*

    • 海和药物的12亿元人民币B轮融资*以及

    • 和誉医药的1.23亿美元D轮融资*

*代表加入高赢之前的职业经历

Professional Experience

Prior to joining Goodwin, Dr. Cui was an associate in the IP and Technology Transactions Groups of Morrison & Foerster LLP (“MoFo”), where he was a key member of the firm’s China Life Sciences practice. During his four-year residency in the firm’s Hong Kong office, he managed, in addition to cross-border licensing and investment transactions, patent dispute matters in China on behalf of MoFo’s U.S. clients, and gained extensive experience in IP dispute resolution in China. During his subsequent five-year residency in MoFo’s San Francisco office, he continued to represent clients in both China and the U.S. in their cross-border technology transactions and investments, and played a leading role in those transactions in the life sciences industry.

While working in MoFo’s Hong Kong office, Dr. Cui was an adjunct faculty member at The Chinese University of Hong Kong (CUHK). During his three-year tenure at CUHK Faculty of Law, he taught the Principles of Intellectual Property course, and established CUHK’s Chinese IP Law course.

Prior to and while attending law school, Dr. Cui worked as a U.S. patent agent in the Boston and New York offices of Ropes & Gray LLP, where he was a member of the Fish & Neave IP Group.

As a graduate student at Harvard, Dr. Cui conceived, established, and maintained a major long-term collaborative project among Harvard Medical School, the University of California, San Diego, and the Chinese Academy of Sciences. His identification of a viral microRNA was featured in the “Spotlight” section of Journal of Virology as an article of significant interest selected by the editors.
专业经验

在加入高赢之前,崔博士是美富律师事务所知识产权组和技术交易组律师,也是该所中国生命科学业务的关键成员。在美富香港办事处执业的四年中,他管理跨境许可和投资交易,同时代表该所的美国客户处理在中国的专利纠纷,并积累了丰富的中国知识产权争议解决经验。在其此后在美富旧金山办事处执业的五年中,他继续代表中美两国的客户处理跨境技术交易和投资项目,并主管与生命科学相关的业务。

在美富香港办事处执业期间,崔博士被香港中文大学聘为特聘讲师。在港中大法律学院任教的三年间,他教授知识产权原理课程,并开创了港中大的中国知识产权法课程。

在上法学院之前和期间,崔博士作为Fish & Neave识产权组的成员在瑞格律师事务所的波士顿和纽约办事处担任美国专利代理人。

为哈佛大学的研究生,他构思、建立并维系了一项由哈佛医学院、加州大学圣地亚哥分校和中国科学院共同参与的重要长期合作项目。他的关于病毒微小RNA 的突破性发现发表在《病毒学学报》(Journal of Virology)的焦点Spotlight专栏,并被编辑特选为极具影响力的文章
Professional Activities

Dr. Cui is a member of American Bar Association, New York State Bar Association, California Lawyers Association, Bar Association of San Francisco, and San Francisco Bay Area Intellectual Property Inn of Court.

Dr. Cui is a frequent guest lecturer and panelist at top universities and law schools in the United States and in China on U.S. patent law, cross-border technology licensing, and IP protection in the life sciences industry.
专业活动

崔博士是美国律师协会、纽约州律师协会、加州律师协会、旧金山律师协会、旧金山湾区识产权法律师学院会员。

崔博士经常担任美国和中国顶尖大学和法学院的客座讲师和座谈会嘉宾,讲谈美国专利法、跨境技术许可和生命科学行业的知识产权保护。

Recognition

Dr. Cui is recognized by Berkeley Center for Law & Technology as one of the “leading practitioners in biotech and life sciences.”

职业认可

崔博士被伯克利法律和技术中心(Berkeley Center for Law & Technology认可为生物技术和生命科学领域的领先执业者之一。

In The News

MELDUNGEN

ACTUALITÉS

相关新闻

Credentials

WERDEGANG

RÉFÉRENCES

专业资格

Education

J.D., 2012
New York University School of Law
(magna cum laude; The Order of the Coif; Weinfeld Fellow; Walter J. Derenberg Prize, NYU Law’s only Convocation Award in IP Law; NYU Journal of Law & Business: Staff Editor (2010-11); Board Member and Senior Articles Editor (2011-12))
Ph.D., Biological Chemistry & Molecular Pharmacology, 2007
Harvard University
B.Sc., Biotechnology, 2000
Peking University
(summa cum laude; Valedictorian; Shuping Scholar; High Distinction Honor)

教育背景

法学博士, 2012
纽约大学法学院
(极优等毕业生magna cum laude;美国杰出法律学会白帽协会(The Order of the Coif)的荣誉会员;Weinfeld Fellow;纽约大学法学院唯一知识产权法毕业生荣誉奖Walter J. Derenberg奖得主;《纽约大学法律与商业学报》(NYU Journal of Law & Business)的论文编辑(2010-11)、资深编辑及编委会委员(2011-12))
生物化学与分子药理学博士, 2007
哈佛大学
生物技术学士, 2000
北京大学
(最优等毕业生summa cum laude;毕业生代表;叔苹奖学金; 毕业生优秀论文)

Admissions

Bar

California
New York

执业资格

司法区

加利福尼亞州
纽约州
Profile Image
Get In Touch
Kontakt
NOUS CONTACTER
联系我们
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

客户信赖我们世界一流的咨询服务,希望获得针对复杂事务性工作与高风险诉讼的建议。我们通过协作式、跨领域的工作方法来解决客户最棘手的问题,涵盖金融、生命科学、私募股权、不动产和技术等多个行业。如需更多信息,请与我们联系。

Search Other Lawyers
ANWALTSSUCHE
Recherche par Pratique
搜寻其他律师